Compare Ryanair Holdings plc (RYAAY) vs Sana Biotechnology Inc (SANA) Price & Performance

Ryanair Holdings plcTrade

Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Ryanair Holdings plc vs Sana Biotechnology Inc — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Ryanair Holdings plc is far larger — about 33.5× Sana Biotechnology Inc's market cap, and Ryanair Holdings plc pays a 1.68% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

	RYAAY	SANA
Market Cap	$29.31B	$873.84M
Sector	Industrials	Health
52-Week High	$73.82	$5.92
52-Week Low	$53.24	$2.68
Enterprise Value	$26.33B	$848.03M
Dividend Yield	1.68%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

RYAAY

US-Iran conflict raises oil prices, worries on economy and stocks' outlook.CNBC · 13 hours agoBearish Ryanair Q2 earnings miss due to fuel cost surge and lower ticket prices amid economic uncertaintyAlex Lavoie · 17 hours agoBearish Ryanair's Q1 profit falls 34% due to rising fuel costs and lower ticket fares amid Middle East tensionsCNBC · 1 day agoBearish View details →

SANA

View details →

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.